Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brent Rexer, MD, PhD
Vanderbilt-Ingram Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama
Birmingham, Alabama, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Baptist Memorial Hospital Memphis
Memphis, Tennessee, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- University of Texas Southwestern Simmons Comprehensive Cancer Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Aug 2017
- Primary completion
- 30 Apr 2021
- Completion
- 20 Mar 2024
- Last update posted
- 14 Nov 2024
- Registered enrollment
- 35
- Registry id
- NCT03238196
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.